Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
| ▸ | SCN2B | O60939 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754239 | 0.87 | NR3C2 (0.71) | NR3C2POLBTRPV1BRD4 | |
| SCHEMBL761147 | 0.86 | NR3C2 (0.70) | NR3C2TRPV1BRD4PLA2G7 | |
| SCHEMBL5088338 | 0.85 | NR3C2 (0.67) | NR3C2POLBALDH1A1BRD4 | |
| SCHEMBL755350 | 0.84 | NR3C2 (0.70) | NR3C2TRPV1BRD4SCN9A | |
| SCHEMBL4530548 | 0.84 | NR3C2 (0.53) | NR3C2POLBALDH1A1XIAPBIRC2 | |
| SCHEMBL755189 | 0.84 | NR3C2 (0.70) | NR3C2BRD4 | |
| SCHEMBL2266367 | 0.82 | NR3C2 (0.67) | NR3C2KMT2AMEN1ALDH1A1BRD4 | |
| SCHEMBL754848 | 0.82 | NR3C2 (0.59) | NR3C2TRPV1BRD4PLA2G7SCN9A | |
| SCHEMBL4522311 | 0.80 | NR3C2 (0.49) | NR3C2POLBKMT2AMEN1ALDH1A1 | |
| Mt-3995 SCHEMBL753911 | 0.79 | NR3C2 (1.00) | NR3C2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | NR3C2 1/4885POLB 3875/4885KMT2A 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.